L. Calvo

Standard versus continuous administration of capecitabine in metastatic breast cancer (GEICAM/2009-05): a randomized, noninferiority phase II trial with a pharmacogenetic analysis.

A. González-Neira, G. Pita, A. Lluch, 2015, The oncologist.

A randomized, open, parallel-group trial to compare the endocrine effects of oral anastrozole (Arimidex) with intramuscular formestane in postmenopausal women with advanced breast cancer.

M. Dowsett, J. Robertson, D. Dodwell, 1999, Annals of oncology : official journal of the European Society for Medical Oncology.

Palbociclib Rechallenge for Hormone Receptor–Positive/HER-Negative Advanced Breast Cancer: Findings from the Phase II BioPER Trial

F. Rojo, L. Comerma, G. Curigliano, 2022, Clinical cancer research : an official journal of the American Association for Cancer Research.

Abstract P3-09-03: A phase II study of pembrolizumab and eribulin in patients with HR-positive/HER2-negative metastatic breast cancer previously treated with anthracyclines and taxanes (KELLY study)

E. L. Miranda, G. Curigliano, A. Prat, 2020, Poster Session Abstracts.

Randomized, phase II trial comparing continuous versus intermittent capecitabine monotherapy for metastatic breast cancer (MBC).

M. Ramos, J. García-Saenz, M. Muñoz, 2009, Journal of Clinical Oncology.

Toxicity and health-related quality of life in breast cancer patients receiving adjuvant docetaxel, doxorubicin, cyclophosphamide (TAC) or 5-fluorouracil, doxorubicin and cyclophosphamide (FAC): impact of adding primary prophylactic granulocyte-colony stimulating factor to the TAC regimen.

A. Lluch, J. Zaluski, M. Martín, 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

Chemotherapy (CT) and hormonotherapy (HT) as neoadjuvant treatment in luminal breast cancer patients: results from the GEICAM/2006-03, a multicenter, randomized, phase-II study.

J. Albanell, A. Lluch, E. Alba, 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

Outcomes of single versus double hormone receptor-positive breast cancer. A GEICAM/9906 sub-study.

A. Lluch, E. Alba, E. Carrasco, 2018, European journal of cancer.

A definition for aggressive disease in patients with HER-2 negative metastatic breast cancer: an expert consensus of the Spanish Society of Medical Oncology (SEOM)

J. Albanell, A. Lluch, L. Calvo, 2017, Clinical and Translational Oncology.